Alloimmunization and Humoral Immune Response in Sickle Cell Disease
Official title: Alloimmunization and Humoral Immune Response to Hemolysis and EPO
Funded at New York Blood Center · NIH-11365818 · Data updated 2026-11-12
This grant studies how red blood cell transfusion can trigger antibodies in people with sickle cell disease and what might reduce that risk.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Blood Center NIH-funded |
| Lab location | 1 site (Rye, UNITED STATES) |
| Project start | July 20, 2020 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $490,395 |
| NIH project number | 5P01HL149626-07 |
| Project ID | NIH-11365818 on NIH RePORTER |
Who could benefit from this research
✓Could help
Sickle cell disease patients who receive blood transfusions and may be at risk for alloimmunization or transfusion reactions.
✕Less likely to help
Patients not requiring transfusions or without alloimmune risk factors may see limited direct benefits.
What this research studies
We aim to understand why many SCD patients develop antibodies after transfusions and how EPO and related metabolic changes influence this process. The work combines patient samples with lab models to explore how EPO-induced asparagine levels affect B cell activity and antibody production, and how hemolysis interacts with these pathways. The project also looks at memory B cell function and T follicular regulatory cells to map who is at higher risk for alloimmunization or delayed reactions, with a focus on translational relevance to transfusion practices.
Why it matters
Potential benefit: Findings could lead to personalized transfusion strategies that reduce alloimmunization and improve safety for SCD patients needing transfusions.
How similar studies have gone: Prior studies have linked EPO and immune responses to transfusion outcomes, supporting potential impact of this approach.
Where this research is happening
-
New York Blood Center
Rye, United States Active
Researchers
- Principal investigator: Yazdanbakhsh, Karina — New York Blood Center
- Study coordinator: Yazdanbakhsh, Karina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.